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this, functional studies of FOXO3a could 
only examine its activity indirectly through 
checking the expression of its inactive form.
FOXO3a has been shown to play an 
important role in mediating the cytotoxic 
effects of chemotherapeutic drugs such as 
doxorubicin (Hui et al., 2008a,b). It has 
been observed that acquisition of chem-
oresistance correlated unexpectedly with 
increased expression and nuclear accumu-
lation of FOXO3a in leukemic cells (Hui 
et al., 2008b) and breast cancer cells (Chen 
et al., 2010). Indeed, examination in breast 
cancer tissue microarrays showed sustained 
nuclear FOXO3a was associated with poor 
prognosis (Chen et al., 2010). It is specu-
lated that FOXO3a engages in a feedback 
mechanism whereby sustained FOXO3a 
activation can enhance hyperactivation of 
the PI3K/Akt pathway (Gomes et al., 2008).
Lam and co-workers in the captioned 
article, report a novel phosphorylation site 
of FOXO3a which appears responsible for 
its nuclear relocation under the action of 
doxorubicin (Ho et al., 2012). They observed 
FOXO3a nuclear relocation as well as induc-
tion of p38 expression following doxorubicin 
treatment and hypothesized that p38 could 
directly regulate FOXO3a and provided con-
crete evidence to support their speculation. 
They elegantly demonstrated that p38 not 
only complexes with FOXO3a with or with-
out doxorubicin treatment, but also directly 
phosphorylates FOXO3a at a novel site, Ser-
7. Phosphorylation of FOXO3a at Ser-7 is a 
key for its relocation to nucleus, as a Ser-7 
phosphorylation-deficient mutant could 
not be localized to nucleus when treated 
with doxorubicin (Ho et al., 2012).
The involvement of the stress activated 
kinase p38 targeting FOXO3a opens further 
horizons for investigation with regard to 
other p38 phosphorylation sites that may 
contribute toward FOXO3a nuclear relo-
calization. Indeed additional p38 phospho-
rylation sites were identified in this study 
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Forkhead box O (FOXO) proteins, are a 
subgroup of transcription factors character-
ized by a conserved DNA-binding forkhead 
domain. FOXO3a is one of the members of 
this subfamily which activate or repress mul-
tiple genes involved in cell cycle regulation, 
apoptosis, DNA damage repair, protection 
against oxidative stress, and metabolism. 
FOXOs are regulated by a broad variety of 
stimuli which control FOXO protein expres-
sion, subcellular localization, DNA binding, 
and transcriptional activity. The biological 
activity of FOXO proteins are primarily reg-
ulated by post-translational modifications, 
including phosphorylation, acetylation, and 
ubiquitination.
The PI3K/Akt (PKB) pathway is one 
of the first and potentially most impor-
tant kinase pathways shown to regulate 
FOXO3a activity (Paradis and Ruvkun, 
1998). Phosphorylation of FOXO3a by Akt 
results in cytoplasmic accumulation and its 
subsequent degradation. ERK (Biggs et al., 
1999; Yang et al., 2008) and JNK (Sunters 
et al., 2006), two of the three canonical 
MAPK pathways (ERK, p38, and JNK), 
have also been shown to activate FOXO3a 
activity, but nothing had previously been 
known with regard the p38 MAPK signal-
ing pathway in relation to FOXO protein 
regulation. Phosphorylations at most of 
the known sites of FOXO3a lead to its 
 translocation into cytoplasm and inacti-
vation (Yang and Hung, 2009). Based on 
which are also targeted by JNK and ERK. 
Furthermore p38 phosphorylation may 
also have other biological functions not yet 
identified. In terms of anti-cancer therapeu-
tics, due to the potent antitumor activity of 
FOXO3a, it has been suggested that drugs 
that activate FOXO3a may be used in com-
bination with other therapeutic agents to 
sensitize tumor cells. The dependence of 
chemotherapeutic-induced cell death on 
p38 activation is well documented.
Ser-7 is the first reported site at which 
phosphorylation can lead to the nuclear 
localization of FOXO3a. It could serve as 
a marker for nuclear FOXO3a as suggested 
by the authors. However, caution should be 
taken when using it as a marker for active 
FOXO3a, for though it is generally acknowl-
edged that nuclear FOXO3a is active, this 
should not be taken for granted. The 
authors did not show directly that the phos-
phorylation at Ser-7 was a causal event of 
FOXO3a activation. As shown in their sup-
plementary data, over-expression of Ser-7 
phosphorylation-deficient mutants could 
still induce the activation of FOXO3a and 
the expression of its target genes (Ho et al., 
2012). Hence the functional importance of 
Ser-7 phosphorylated FOXO3a remains to 
be further investigated.
This article mainly used MCF7, a doxo-
rubicin-sensitive breast cancer cell line, as a 
model. However, the functions of FOXO3a 
have been indicated to change from pro-
apoptotic to pro-survival in cell lines with 
acquire resistance to doxorubicin (Hui et al., 
2008a; Wilson et al., 2011). Therefore, besides 
fully exploring the functions of nuclear Ser-7 
phosphorylated FOXO3a in the current cell 
line model, it would also be interesting to 
study the role of FOXO3a phosphorylation 
at Ser-7 in acquired doxorubicin resist-
ance. It was noted that Ser-7 phosphoryla-
tion by doxorubicin also occurs in prostate 
cancer cell lines, and was suggested that it 
may be a universal event. As mentioned 
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FOXO3a. Furthermore, it has provided a 
nuclear FOXO3a marker, anti-P-FOXO3a-
(Ser-7) which has high potential for appli-
cation on clinical samples, thus implicating 
some very interesting and worthwhile fur-
ther research directions.
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earlier, nuclear accumulation of FOXO3a 
and hyper-active PI3K-AKT pathway as 
observed with acquisition of doxorubicin 
resistance in both doxorubicin-resistant 
breast cancer cell line and leukemic cell line 
(Hui et al., 2008a,b; Chen et al., 2010). Is 
the nuclear localization of FOXO3a in the 
Doxorubicin-resistant cells is also caused by 
Ser-7 phosphorylation or is there any other 
mechanism? Is the Ser-7-phosphorylated 
FOXO3a functionally active in mediating the 
drug resistance? More importantly, can this 
marker be used in predicting doxorubicin 
response of tumor cells? Such application 
would be clinically useful in guiding the 
choice of chemotherapeutic regime.
The authors report they confirm that 
p38 mediates FOXO3a phosphorylation 
on Ser-7 in vivo, by the use of a phospho-
specific antibody, anti-P-FOXO3a-(Ser-7) 
which they had generated and validated. 
This in vivo study however was performed 
on MCF7 breast cancer cell lines that were 
co-transfected with pCMV-FLAG-FOXO3a 
and increasing amounts of pEGFP-p38α. It 
could be argued that this disagrees with the 
conventional definition of in vivo study, as 
“in vivo” generally refers to using whole, liv-
ing organisms whilst cell line study is usu-
ally considered as “in vitro.” Regardless, this 
article presented solid evidences to support 
the definitive conclusion that p38 directly 
phosphorylated FOXO3a at Ser-7 and pro-
vides new insights into the regulation of 
